What is the market price of giritinib in China? Drug Pricing and Purchasing Access

Gilitinib is a targeted drug used to treat acute myeloid leukemia (AML), especially for patients who have received other treatments and have FLT3 mutations. FLT3 is a gene mutation commonly found in malignant tumors, leading to uncontrolled cell proliferation. Giritinib effectively inhibits the growth and spread of tumor cells by selectively inhibiting the activity of these mutant FLT3 tyrosine kinases.

In clinical applications, giritinib is typically used in adult patients with relapsed or refractory acute myeloid leukemia, especially those with detectedFLT3-ITD or FLT3-TKD mutations. Studies have shown that giritinib has a significant effect in improving patients' overall survival and progression-free survival. Patients using this drug can achieve better clinical outcomes after receiving treatment, which is also important for improving quality of life.

In the Chinese market, the original drug of gilitinib has been launched, but because it has not yet been included in medical insurance, the financial burden on patients is still heavy. The common specification is 40mg, each box contains 21 tablets, and is usually sold for about more than 20,000 yuan. This price level puts many patients under greater financial pressure during long-term treatment, especially if continuous medication is required.

In terms of purchasing channels, patients can obtain giritinib through multiple channels. First of all, it can be purchased in the hospital pharmacy. Usually large hospitals will provide this medicine directly. Secondly, some online drug sales platforms may also provide purchasing services for the drug, but attention should be paid to choosing formal channels to ensure the quality and source of the drug. In addition, some drug agency companies may also assist patients in purchasing drugs, but such channels generally need to confirm their legality and credibility.

Reference materials:https://www.xospata.com/